Description
VACUTRO Tablets 49 mg + 51 mg TP (Pack of 28 Tablets)
Potent Dual-Action Therapy for Chronic Heart Failure
VACUTRO Tablets combine Sacubitril 49 mg and Valsartan 51 mg in a single tablet, delivering an effective treatment option for patients with chronic heart failure (NYHA Class II–IV). This combination drug belongs to the class of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) and has been shown to significantly reduce hospitalization and cardiovascular mortality in heart failure patients.
Sacubitril helps enhance beneficial neurohormonal pathways, while Valsartan blocks the harmful effects of the renin-angiotensin-aldosterone system, together improving heart function and patient outcomes.
Key Benefits:
-
Reduces risk of cardiovascular death and heart failure hospitalization
-
Improves symptoms and quality of life in heart failure patients
-
Dual mechanism for comprehensive heart failure management
-
Suitable for once or twice daily dosing as per physician’s guidance
Directions for Use:
Take as prescribed by your healthcare provider. Typically administered twice daily with or without food.
Precautions:
Avoid use during pregnancy and in combination with ACE inhibitors. Regular monitoring of blood pressure, kidney function, and electrolytes is recommended.
Reviews
There are no reviews yet.